<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00601848</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 05503</org_study_id>
    <secondary_id>CDR0000583050</secondary_id>
    <nct_id>NCT00601848</nct_id>
  </id_info>
  <brief_title>Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura</brief_title>
  <official_title>A Phase II Study of Pleural Photodynamic Therapy for Patients With Non-small Cell Lung Cancer and Pleural Spread</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Photodynamic therapy uses a drug, such as porfimer sodium, that is absorbed by&#xD;
      tumor cells. The drug becomes active when it is exposed to light. When the drug is active,&#xD;
      tumor cells are killed. Giving photodynamic therapy during surgery may kill any tumor cells&#xD;
      that remain after surgery.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects and how well photodynamic therapy&#xD;
      given during surgery works in treating patients with resectable non-small cell lung cancer&#xD;
      that has spread to the pleura.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the overall survival rate of patients with non-small cell lung cancer&#xD;
           (NSCLC) and malignant pleural spread treated with standard front-line chemotherapy&#xD;
           followed by surgical resection and intra-operative porfimer sodium (Photofrin®)-mediated&#xD;
           photodynamic therapy.&#xD;
&#xD;
        -  To determine the feasibility and toxicities of standard front-line chemotherapy followed&#xD;
           by surgical resection and intra-operative Photofrin®-mediated photodynamic therapy in&#xD;
           these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the progression-free survival and pleural progression-free survival of&#xD;
           these patients.&#xD;
&#xD;
        -  To determine the absolute Photofrin® levels in tumor and normal tissues resected from&#xD;
           these patients using spectrofluorometric methods.&#xD;
&#xD;
        -  To determine the tumor to normal tissue ratios of Photofrin® in these patients.&#xD;
&#xD;
        -  To measure the optical properties of tumor and normal tissues in situ.&#xD;
&#xD;
        -  To compare the Photofrin® concentration of tumor and normal tissues made with the in&#xD;
           situ measurements to the measurements made with spectrofluorometric method.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive 2-4 courses of standard front-line chemotherapy prior to surgery (if they&#xD;
      have not completed the front-line chemotherapy).&#xD;
&#xD;
      Patients receive porfimer sodium (Photofrin®) IV over 5-15 minutes. Approximately 24 hours&#xD;
      after receiving porfimer sodium, patients undergo surgery to remove the primary tumor and the&#xD;
      pleural disease to a thickness of 5 mm or less*. Patients then undergo intraoperative&#xD;
      photodynamic therapy to the residual disease. Some patients may undergo postoperative&#xD;
      radiotherapy to the mediastinum and/or surgical scar if clinically indicated.&#xD;
&#xD;
      NOTE: *If the disease cannot be resected to less than 5 mm, PDT will not be delivered&#xD;
&#xD;
      Tumor and normal tissue samples are obtained from the surgical specimen and examined prior to&#xD;
      light delivery at the time of thoracotomy, and after light delivery. Tissue samples are&#xD;
      analyzed for porphyrin levels using a spectrofluorometric assay of tissue specimens and an in&#xD;
      situ optical method intra-operatively. Samples are also assessed for V-cadherin, markers for&#xD;
      oxidative stress, markers associated with photosensitizer uptake, markers for angiogenesis,&#xD;
      markers for hypoxia, activation of signaling pathway components (including EGFR, p38 MAPK,&#xD;
      Akt, and p42/44 MAPK) via immunohistochemistry.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual and change in standards of care&#xD;
  </why_stopped>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity Assessment of Pleural Photodynamic Therapy</measure>
    <time_frame>One year</time_frame>
    <description>Toxicities of PDT as defined by CTCAE v4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Subject survival post PDT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pleural Progression-free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Amount of time from PDT to disease progression in pleura</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Amount of time from PDT to disease progression at any site in the body</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Photofrin® Uptake</measure>
    <time_frame>90 days</time_frame>
    <description>Measured uptake of PDT drug</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Photodynamic Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <arm_group_label>Photodynamic Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>porfimer sodium</intervention_name>
    <arm_group_label>Photodynamic Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <arm_group_label>Photodynamic Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Photodynamic Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>spectroscopy</intervention_name>
    <arm_group_label>Photodynamic Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <arm_group_label>Photodynamic Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed non-small cell lung cancer (NSCLC)&#xD;
&#xD;
               -  Must have clinical and/or pathological evidence of pleural spread&#xD;
&#xD;
               -  Primary tumor must be resectable as assessed by the attending thoracic surgeon&#xD;
&#xD;
          -  Patients who have received or are currently receiving two-to-four courses of standard&#xD;
             front-line chemotherapy are eligible&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Must be medically fit to tolerate surgery&#xD;
&#xD;
          -  No CTCAE v3.0 grade III-IV elevations in liver transaminases&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  No known HIV infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior treatment for NSCLC except pleurodesis or standard front-line chemotherapy&#xD;
&#xD;
          -  No prior pemetrexed disodium chemotherapy&#xD;
&#xD;
          -  No prior mantle radiotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy or radiotherapy during the active study treatment period&#xD;
&#xD;
               -  Post-operative radiotherapy will be administered as clinically indicated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Cengel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.gov/clinicaltrials</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 25, 2008</study_first_submitted>
  <study_first_submitted_qc>January 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <results_first_submitted>April 24, 2020</results_first_submitted>
  <results_first_submitted_qc>November 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 24, 2020</results_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>malignant pleural effusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihematoporphyrin Ether</mesh_term>
    <mesh_term>Trioxsalen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Photodynamic Therapy</title>
          <description>PDT&#xD;
chemotherapy&#xD;
porfimer sodium&#xD;
immunohistochemistry staining method&#xD;
laboratory biomarker analysis&#xD;
spectroscopy&#xD;
therapeutic conventional surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm</title>
          <description>PDT&#xD;
chemotherapy&#xD;
porfimer sodium&#xD;
immunohistochemistry staining method&#xD;
laboratory biomarker analysis&#xD;
spectroscopy&#xD;
therapeutic conventional surgery</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" spread="10.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Toxicity Assessment of Pleural Photodynamic Therapy</title>
        <description>Toxicities of PDT as defined by CTCAE v4.0</description>
        <time_frame>One year</time_frame>
        <population>The study was terminated. Despite all possible efforts to contact the PI/study team members, no data are available to be reported</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>PDT&#xD;
chemotherapy&#xD;
porfimer sodium&#xD;
immunohistochemistry staining method&#xD;
laboratory biomarker analysis&#xD;
spectroscopy&#xD;
therapeutic conventional surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity Assessment of Pleural Photodynamic Therapy</title>
          <description>Toxicities of PDT as defined by CTCAE v4.0</description>
          <population>The study was terminated. Despite all possible efforts to contact the PI/study team members, no data are available to be reported</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Subject survival post PDT</description>
        <time_frame>5 years</time_frame>
        <population>The study was terminated. Despite all possible efforts to contact the PI/study team members, no data are available to be reported</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>PDT&#xD;
chemotherapy&#xD;
porfimer sodium&#xD;
immunohistochemistry staining method&#xD;
laboratory biomarker analysis&#xD;
spectroscopy&#xD;
therapeutic conventional surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Subject survival post PDT</description>
          <population>The study was terminated. Despite all possible efforts to contact the PI/study team members, no data are available to be reported</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pleural Progression-free Survival</title>
        <description>Amount of time from PDT to disease progression in pleura</description>
        <time_frame>5 years</time_frame>
        <population>The study was terminated. Despite all possible efforts to contact the PI/study team members, no data are available to be reported</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>PDT&#xD;
chemotherapy&#xD;
porfimer sodium&#xD;
immunohistochemistry staining method&#xD;
laboratory biomarker analysis&#xD;
spectroscopy&#xD;
therapeutic conventional surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Pleural Progression-free Survival</title>
          <description>Amount of time from PDT to disease progression in pleura</description>
          <population>The study was terminated. Despite all possible efforts to contact the PI/study team members, no data are available to be reported</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Amount of time from PDT to disease progression at any site in the body</description>
        <time_frame>5 years</time_frame>
        <population>The study was terminated. Despite all possible efforts to contact the PI/study team members, no data are available to be reported</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>PDT&#xD;
chemotherapy&#xD;
porfimer sodium&#xD;
immunohistochemistry staining method&#xD;
laboratory biomarker analysis&#xD;
spectroscopy&#xD;
therapeutic conventional surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Amount of time from PDT to disease progression at any site in the body</description>
          <population>The study was terminated. Despite all possible efforts to contact the PI/study team members, no data are available to be reported</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Photofrin® Uptake</title>
        <description>Measured uptake of PDT drug</description>
        <time_frame>90 days</time_frame>
        <population>The study was terminated. Despite all possible efforts to contact the PI/study team members, no data are available to be reported</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>PDT&#xD;
chemotherapy&#xD;
porfimer sodium&#xD;
immunohistochemistry staining method&#xD;
laboratory biomarker analysis&#xD;
spectroscopy&#xD;
therapeutic conventional surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Photofrin® Uptake</title>
          <description>Measured uptake of PDT drug</description>
          <population>The study was terminated. Despite all possible efforts to contact the PI/study team members, no data are available to be reported</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Arm</title>
          <description>PDT&#xD;
chemotherapy&#xD;
porfimer sodium&#xD;
immunohistochemistry staining method&#xD;
laboratory biomarker analysis&#xD;
spectroscopy&#xD;
therapeutic conventional surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Keith A Cengel, MD, PhD</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>(215) 615-5312</phone>
      <email>cengel@pennmedicine.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

